1. Home
  2. CMDB vs CAPR Comparison

CMDB vs CAPR Comparison

Compare CMDB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Costamare Bulkers Holdings Limited

CMDB

Costamare Bulkers Holdings Limited

SELL

Current Price

$20.46

Market Cap

507.2M

Sector

N/A

ML Signal

SELL

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

SELL

Current Price

$7.47

Market Cap

584.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CMDB
CAPR
Founded
2023
2005
Country
Monaco
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
507.2M
584.9M
IPO Year
2024
2011

Fundamental Metrics

Financial Performance
Metric
CMDB
CAPR
Price
$20.46
$7.47
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $27.00
AVG Volume (30 Days)
51.3K
★ 2.5M
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.52
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.29
$2.96
52 Week High
$24.76
$40.37

Technical Indicators

Market Signals
Indicator
CMDB
CAPR
Relative Strength Index (RSI) 41.94 40.60
Support Level $16.35 $7.37
Resistance Level $23.16 $10.12
Average True Range (ATR) 0.93 0.55
MACD -0.34 -0.10
Stochastic Oscillator 14.55 2.66

Price Performance

Historical Comparison
CMDB
CAPR

About CMDB Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing transportation of dry bulk commodities globally for a broad range of customers. Its vessels transport a broad range of bulks, such as iron ore, coal and grains and minor bulks, such as bauxite, phosphate fertilizers and steel products, across shipping routes globally. The company's vessel fleet includes Current Dry Bulk Fleet, Chartered-In Vessels Fleet, and Chartered-In Newbuilding Vessels. It operates under one reportable segment, that of operating dry bulk vessels.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: